Cyxone's TO 2 series warrant options exercised to around 98.7%
The subscription period to purchase warrants in TO 2 ended on September 29, 2017, and during the period, 2,467,119 warrant options were exercised for the equivalent number of shares, corresponding to a subscription ratio of around 98.7%. Cyxone thereby receives some SEK 12.3 million before issue costs.
2,467,119 shares will be registered with the Swedish Companies Registration Office at the beginning of November 2017. Following this registration, share captial in the comapny will amount to 1,343,253.66 distributed over 17,798,111 shares. Cyxone will thus receive approximately SEK 11.7 million after issue costs.
Corpura Fondkommission AB are acting as financial advisors for this transaction. Eminova Fondkommission AB is the issuer. Cyxone's Certified Adviser on the Nasdaq First North is Erik Penser Bank.
Cyxone AB (publ)
Kjell G. Stenberg, CEO
Tel: +46 (0)723 816168
211 22 Malmö
This is information that Cyxone AB is required to publish under the EU Market Abuse Directive. The information was provided under the auspices of the above contact person for publication on October 5, 2017 at 13:00 CET.
Cyxone AB (publ.) is a biopharmaceutical company that develops drugs based on cyclotides, a class of natural plant protein. Cyclotide technology has the potential to provide new drugs with beneficial pharmacological effects on diseases that currently lack safe and effective treatments. The company is focusing on the development of substances that inhibit key processes in cells that are typically associated with various immune disorders, such as multiple sclerosis and rheumatoid arthritis. Cyxone's Certified Adviser on the Nasdaq First North is Erik Penser Bank, which can be reached on +46 (0) 8 46 38 000.